The stock of Altimmune Inc (ALT) has gone down by -12.31% for the week, with a -24.69% drop in the past month and a -37.08% drop in the past quarter. The volatility ratio for the week is 7.22%, and the volatility levels for the past 30 days are 8.70% for ALT.. The simple moving average for the past 20 days is -15.99% for ALT’s stock, with a 29.82% simple moving average for the past 200 days.
Is It Worth Investing in Altimmune Inc (NASDAQ: ALT) Right Now?
Company’s 36-month beta value is 0.13.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALT is 70.17M, and currently, short sellers hold a 25.27% ratio of that floaft. The average trading volume of ALT on April 16, 2024 was 5.15M shares.
ALT) stock’s latest price update
Altimmune Inc (NASDAQ: ALT) has experienced a decline in its stock price by -5.51 compared to its previous closing price of 7.99. However, the company has seen a fall of -12.31% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-12 that Altimmune is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases. Their lead drug candidate, Pemvidutide, targets glucagon-like peptide-1 and glucagon receptors to produce weight loss with reduced side effects. Pemvidutide has shown promising results in clinical trials for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and the company is seeking partnerships for further development.
Analysts’ Opinion of ALT
Many brokerage firms have already submitted their reports for ALT stocks, with Goldman repeating the rating for ALT by listing it as a “Neutral.” The predicted price for ALT in the upcoming period, according to Goldman is $13 based on the research report published on January 24, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see ALT reach a price target of $6, previously predicting the price at $20. The rating they have provided for ALT stocks is “Neutral” according to the report published on March 22nd, 2023.
Goldman gave a rating of “Buy” to ALT, setting the target price at $20 in the report published on December 01st of the previous year.
ALT Trading at -22.66% from the 50-Day Moving Average
After a stumble in the market that brought ALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.12% of loss for the given period.
Volatility was left at 8.70%, however, over the last 30 days, the volatility rate increased by 7.22%, as shares sank -23.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.58% lower at present.
During the last 5 trading sessions, ALT fell by -12.31%, which changed the moving average for the period of 200-days by +110.31% in comparison to the 20-day moving average, which settled at $8.87. In addition, Altimmune Inc saw -32.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALT starting from Drutz David, who purchase 300 shares at the price of $2.88 back on Aug 15 ’23. After this action, Drutz David now owns 29,785 shares of Altimmune Inc, valued at $862 using the latest closing price.
Stock Fundamentals for ALT
Current profitability levels for the company are sitting at:
- -196.03 for the present operating margin
- -76.88 for the gross margin
The net margin for Altimmune Inc stands at -203.67. The total capital return value is set at -0.42. Equity return is now at value -46.63, with -42.36 for asset returns.
Based on Altimmune Inc (ALT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -112.98. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 3630.87.
Currently, EBITDA for the company is -83.03 million with net debt to EBITDA at 1.72. When we switch over and look at the enterprise to sales, we see a ratio of 940.78. The receivables turnover for the company is 0.09for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.25.
Conclusion
In a nutshell, Altimmune Inc (ALT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
